Treatment News : Chinese Study Challenges Treatment as Prevention Strategy

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
E-newsletters
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join
Username:
Password:

Back to home » Treatment News » December 2012

Most Popular Links
Most Popular Lessons

The HIV Life Cycle

Shingles

Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV

15 Years Ago In POZ


More Treatment News

Click here for more news

Have news about HIV? Send press releases, news tips and other announcements to news@poz.com.


emailprint

December 6, 2012

Chinese Study Challenges Treatment as Prevention Strategy

A large Chinese study claims that treating HIV is much less effective at preventing transmission of the virus among serodiscordant couples than previously believed, MedPage Today reports. The study, published in the online edition of the Lancet, claims that treatment only reduced transmission rates by 26 percent. This challenges the HPTN 052 trial of 2011, which found that antiretroviral (ARV) treatment reduced transmission rates by 96 percent.

Both the HPTN 052 trial and the Chinese study looked at heterosexual couples, but the Chinese study looked at serodiscordant relationships outside the confines of a tightly controlled research study.

Using records from Chinese epidemiology and treatment databases covering 2003 through 2011, Yiming Shao, MD, of the Chinese Center for Disease Control and Prevention in Beijing and colleagues examined data on 38,862 serodiscordant couples, including 101,295 person-years of follow-up for the HIV-negative partners. They found that, among the 14,805 couples in which the HIV-positive partner was not on ARVs, the rate of transmission was 2.6 per 100 person years; while among the 24,057 couples in which the HIV-positive partner was on treatment, the rate of transmission was 1.3 per 100 person-years.

Researchers could only state with certainty that the 26 percent reduction in the rate of transmission was significant in the first year of treatment; the reduction lost significance in subsequent years in their statistical analysis. They wrote that more research is needed to understand whether the benefits of treatment as prevention endure over time, and to deduce how data from studies like this can be applied to the real world.

How these findings compare with those of HPTN 052, and how they might affect the treatment as prevention strategy will be topics of considerable importance to the HIV community. Look to POZ and AIDSmeds for further developments.

To read the MedPage Today report, click here.

To read the Lancet study abstract, click here.

Search: HIV, treatment as prevention, Chinese, study, serodiscordant couples, antiretrovirals, HPTN 052 trial, ARVs, transmission, reduction.


Scroll down to comment on this story.



Name:

(will display; 2-50 characters)

Email:

(will NOT display)

City:

(will display; optional)

Comment (500 characters left):

(Note: The POZ team reviews all comments before they are posted. Please do not include either ":" or "@" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules



Hide comments

Previous Comments:


  comments 1 - 3 (of 3 total)    

Mark MacDonald, Vancouver Canada, 2012-12-19 11:01:55
Consider the source. This is a government which denied the mere existence of HIV in its population for decades. Secondly, how well treated were those on ARV? Were they actually suppressed? It's no good saying ARV is no good at reducing transmission if the parameters of compliance and suppression aren't met. Give me a controlled study over a mere review of medical records any day. Without more detail about this study, reporting on it can become "scare-mongering". Super-infection ringing bells?

wisewoof, Dayton, 2012-12-19 10:41:12
1st - way, way too many unaccounted variables. And second The Chinese Interpretation is Antiretroviral therapy for HIV-positive individuals in serodiscordant couples reduced HIV transmission across China, which suggests that the treatment-as-prevention approach is a feasible public health prevention strategy on a national scale in a developing country context. The durability and generalisability of such protection, however, needs to be further studied.

Richard Jefferys, New York, 2012-12-06 15:57:26
The headline to this piece says "Chinese Study Challenges Treatment as Prevention Strategy" But the study says "That our results show a significant (p less than 0·0001) 26% reduction in HIV transmission under real-world conditions in a developing country suggests that such a public health prevention strategy is feasible on a national scale and helps to validate the WHO recommendation in support of the treatment-as-prevention approach."

comments 1 - 3 (of 3 total)    


[Go to top]


Join POZ Facebook Twitter Google+ MySpace YouTube Tumblr Flickr
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar


    fokisi
    Long Beach
    California


    koffeeboss
    Tucson
    Arizona


    max38man
    Chicago
    Illinois


    jap022964
    el dorado
    Arkansas
Click here to join POZ Personals!
Ask POZ Pharmacist

Talk to Us
Poll
Have you ever been tested for hepatitis C?
Yes
No

Survey
Pop Watch

more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2014 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.